HUTCHMED Highlights Data at ESMO and ASH

Summary by AI BETAClose X

HUTCHMED announced that new and updated clinical data for several of its compounds will be presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting. Presentations will include data from a first-in-human study of HMPL-A83 in advanced solid tumors, the phase II part of the FRUSICA-2 registration study for fruquintinib and sintilimab in renal cell carcinoma, and results from a phase II/III study of surufatinib in combination with camrelizumab and chemotherapy for metastatic pancreatic cancer. Additionally, final long-term results for sovleplenib in chronic primary immune thrombocytopenia will be presented at the ASH meeting.

Disclaimer*

UK 100

Latest directors dealings